JP2023514611A - タンパク質ベースの精製マトリックス及びその使用方法 - Google Patents

タンパク質ベースの精製マトリックス及びその使用方法 Download PDF

Info

Publication number
JP2023514611A
JP2023514611A JP2022549696A JP2022549696A JP2023514611A JP 2023514611 A JP2023514611 A JP 2023514611A JP 2022549696 A JP2022549696 A JP 2022549696A JP 2022549696 A JP2022549696 A JP 2022549696A JP 2023514611 A JP2023514611 A JP 2023514611A
Authority
JP
Japan
Prior art keywords
seq
biologic
amino acid
matrix
purification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022549696A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514611A5 (https=
Inventor
エム． ルジンブール，ケリー
ズリッキー，マイケル
Original Assignee
アイソレア バイオ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイソレア バイオ，インコーポレイテッド filed Critical アイソレア バイオ，インコーポレイテッド
Publication of JP2023514611A publication Critical patent/JP2023514611A/ja
Publication of JP2023514611A5 publication Critical patent/JP2023514611A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Water Supply & Treatment (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
JP2022549696A 2020-02-19 2021-02-19 タンパク質ベースの精製マトリックス及びその使用方法 Pending JP2023514611A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062978615P 2020-02-19 2020-02-19
US62/978,615 2020-02-19
PCT/US2021/018805 WO2021168270A1 (en) 2020-02-19 2021-02-19 Protein-based purification matrices and methods of using the same

Publications (2)

Publication Number Publication Date
JP2023514611A true JP2023514611A (ja) 2023-04-06
JP2023514611A5 JP2023514611A5 (https=) 2024-03-18

Family

ID=77391793

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022549696A Pending JP2023514611A (ja) 2020-02-19 2021-02-19 タンパク質ベースの精製マトリックス及びその使用方法

Country Status (5)

Country Link
US (2) US20230099707A1 (https=)
EP (1) EP4107167A4 (https=)
JP (1) JP2023514611A (https=)
AU (1) AU2021222032A1 (https=)
WO (1) WO2021168270A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12269847B2 (en) 2018-08-16 2025-04-08 Donaldson Company, Inc. Genetically encoded polypeptide for affinity capture and purification of biologics
US20230099707A1 (en) * 2020-02-19 2023-03-30 Isolere Bio, Inc. Protein-based purification matrices and methods of using the same
EP4554958A2 (en) * 2022-07-12 2025-05-21 Donaldson Company, Inc. Compositions and methods for improving viral transduction
EP4622990A1 (en) 2022-11-21 2025-10-01 CHRETO ApS Method for purification of a target product using affinity purification technology
EP4630444A1 (en) * 2022-12-08 2025-10-15 CSL Behring LLC Dissociable envelope binding proteins and uses thereof
WO2024169990A1 (zh) * 2023-02-13 2024-08-22 浙江大学绍兴研究院 双特异性抗体及其应用
EP4467563A1 (en) * 2023-05-23 2024-11-27 JLP Health GmbH Ldlr derived polypeptides for anti-viral uses
EP4688822A1 (en) * 2023-05-23 2026-02-11 JLP Health GmbH Ldlr derived polypeptides for anti-viral uses
CN121794390A (zh) 2023-07-18 2026-04-03 维伟生物技术有限公司 纯化用树脂及其使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020037100A1 (en) * 2018-08-16 2020-02-20 Isolere Bio, Inc. Genetically encoded polypeptide for affinity capture and purification of biologics

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496926A (en) * 1992-01-19 1996-03-05 Yeda Research And Development Co. Ltd. Process of preparing a soluble LDL receptor
AU3867400A (en) 1999-03-19 2000-10-09 Duke University Methods of using bioelastomers
US20050255554A1 (en) * 2000-03-20 2005-11-17 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
WO2006110292A2 (en) * 2005-03-25 2006-10-19 The Regents Of The University Of California Temperature-triggered immobilization and purification of antibodies
CA2663047A1 (en) * 2006-09-06 2008-03-13 Phase Bioscience, Inc. Therapeutic elastin-like polypeptide (elp) fusion proteins
US8609621B2 (en) 2010-11-15 2013-12-17 E I Du Pont De Nemours And Company Acid-cleavable linkers exhibiting altered rates of acid hydrolysis
EP2673297A2 (en) * 2011-02-11 2013-12-18 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
EP2668962B1 (en) * 2012-05-29 2016-10-26 Albert-Ludwigs-Universität Freiburg Protein assembler
WO2014026054A2 (en) * 2012-08-10 2014-02-13 University Of Southern California CD20 scFv-ELPs METHODS AND THERAPEUTICS
US9616138B1 (en) * 2013-09-26 2017-04-11 University Of South Florida Cargo carrying nanoparticles
EP3052521A1 (en) * 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN104725515B (zh) * 2015-03-20 2017-11-14 扬州大学 一种类弹性蛋白多肽与柯萨奇腺病毒受体融合蛋白及其制备方法和应用
US10385115B2 (en) * 2015-03-26 2019-08-20 Duke University Fibronectin type III domain-based fusion proteins
CN105175554B (zh) 2015-10-26 2018-09-25 扬州大学 一种类弹性蛋白多肽与热应激蛋白90α融合蛋白及其制备方法和应用
US10633662B2 (en) 2015-11-10 2020-04-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulating AAV infection
US11149060B2 (en) * 2016-02-19 2021-10-19 University Of Delaware Functionalized nanoparticles for enhanced affinity precipitation of proteins
JP2020500150A (ja) * 2016-09-23 2020-01-09 デューク ユニバーシティ 下限臨界溶液温度挙動を有する非反復かつ非構造的ポリペプチド
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
US11464867B2 (en) 2018-02-13 2022-10-11 University Of Southern California Multimeric elastin-like polypeptides
CA3098565A1 (en) * 2018-04-29 2019-11-07 Claire G. ZHANG Scalable clarification process for recombinant aav production
CN114746552B (zh) 2019-11-25 2024-11-08 东曹株式会社 改良腺相关病毒结合性蛋白、该蛋白的制造方法以及使用了该蛋白的腺相关病毒吸附剂
US20230340426A1 (en) * 2020-02-19 2023-10-26 Isolere Bio, Inc. Protein-based purification matrices and methods of using the same
US20230099707A1 (en) * 2020-02-19 2023-03-30 Isolere Bio, Inc. Protein-based purification matrices and methods of using the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020037100A1 (en) * 2018-08-16 2020-02-20 Isolere Bio, Inc. Genetically encoded polypeptide for affinity capture and purification of biologics

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ACTA MICROBIOLOGICA SINICA, vol. 61, JPN6025010608, 2021, pages 621 - 630, ISSN: 0005550697 *
ARCH. VIROL., vol. 161, JPN6025010607, 2016, pages 279 - 287, ISSN: 0005550696 *
BIOCHEMISTRY, vol. 34, JPN6025010606, 1995, pages 14474 - 14481, ISSN: 0005758127 *
NAT. COMMUN., vol. Vol. 9:1029, JPN6025052210, 2018, pages 1 - 12, ISSN: 0005758128 *
PROC. NATL. ACAD. SCI. USA, vol. 110, no. 18, JPN6025010604, 2013, pages 7306 - 7311, ISSN: 0005758125 *
PROC. NATL. ACAD. SCI. USA, vol. 96, no. 22, JPN6025010605, 1999, pages 12766 - 12771, ISSN: 0005758126 *

Also Published As

Publication number Publication date
US20220010288A1 (en) 2022-01-13
US20230099707A1 (en) 2023-03-30
EP4107167A1 (en) 2022-12-28
AU2021222032A1 (en) 2022-09-15
EP4107167A4 (en) 2024-04-03
US11591576B2 (en) 2023-02-28
WO2021168270A1 (en) 2021-08-26
AU2021222032A9 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
US11591576B2 (en) Protein-based purification matrices and methods of using the same
JP2023515469A (ja) Ａａｖ結合ポリペプチドを含む精製マトリックス及びその使用方法
McNamara et al. Modern techniques for the isolation of extracellular vesicles and viruses
CN112048005B (zh) 新型冠状病毒s蛋白片段多倍体及其制备方法、检测试剂盒、疫苗及药物
US12173307B2 (en) Methods for the purification of viral vectors
US20230340426A1 (en) Protein-based purification matrices and methods of using the same
ES2354715T3 (es) Procedimiento para mejorar el aislamiento de proteínas producidas de manera recombinante.
JP2023514611A5 (https=)
US20240390517A1 (en) Aav8 capsid variants with enhanced liver targeting
JP2025510977A (ja) エンベロープ型ウイルスを精製する方法
Gashti et al. Purification of recombinant vesicular stomatitis virus-based HIV vaccine candidate
RU2853929C1 (ru) Способы удаления свободного фактора viii из препаратов лентивирусных векторов, модифицированных для экспрессии указанного белка
US20250382336A1 (en) Functionalized ubx protein materials for enhanced purification of antibodies
TW202417469A (zh) 純化供用於疫苗組成物之具有疏水性膜結構域的病毒蛋白的下游程序
US20240076320A1 (en) Downstream process for purification of viral proteins with hydrophobic membrane domain for use in vaccine compositions
Bakhshizadeh-Gashti Purification strategy development for the recombinant vesicular stomatitis virus (rVSV) based HIV vaccine
WO2026033062A1 (en) Purification of bionanoparticles
CN121794390A (zh) 纯化用树脂及其使用方法
Labisch et al. Lab-Scale Tools for Advanced LV Downstream Processing
Affinity et al. Tagging Retrovirus Vectors with a Metal

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250314

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250916

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260420